Wells Fargo
ABCL icon

Wells Fargo’s AbCellera Biologics ABCL Stock Holding History

Wells Fargo’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
60,335
+44,435
+279% +$217K ﹤0.01% 4673
2026
Q1 		$55.5K Buy
15,900
+1,000
+7% +$3.6K ﹤0.01% 5423
2025
Q4 		$51K Buy
14,900
+1,900
+15% +$8.48K ﹤0.01% 5575
2025
Q3 		$65.4K Buy
13,000
+1,200
+10% +$5.29K ﹤0.01% 5475
2025
Q2 		$40.5K Sell
11,800
-1,330
-10% -$3.31K ﹤0.01% 5584
2025
Q1 		$29.3K Hold
13,130
– – ﹤0.01% 5580
2024
Q4 		$38.5K Buy
13,130
+250
+2% +$696 ﹤0.01% 5571
2024
Q3 		$33.5K Sell
12,880
-2,800
-18% -$7.76K ﹤0.01% 5494
2024
Q2 		$46.4K Sell
15,680
-12,436
-44% -$47.1K ﹤0.01% 5321
2024
Q1 		$127K Sell
28,116
-2,200
-7% -$11.2K ﹤0.01% 4752
2023
Q4 		$173K Sell
30,316
-6,525
-18% -$30.2K ﹤0.01% 4550
2023
Q3 		$169K Sell
36,841
-75,139
-67% -$457K ﹤0.01% 4465
2023
Q2 		$723K Sell
111,980
-31,156
-22% -$213K ﹤0.01% 3679
2023
Q1 		$1.08M Buy
143,136
+58,806
+70% +$534K ﹤0.01% 3321
2022
Q4 		$854K Buy
84,330
+7,441
+10% +$86K ﹤0.01% 3338
2022
Q3 		$760K Buy
76,889
+3,798
+5% +$41.7K ﹤0.01% 3413
2022
Q2 		$778K Buy
73,091
+10,040
+16% +$85K ﹤0.01% 3454
2022
Q1 		$615K Sell
63,051
-29,132
-32% -$276K ﹤0.01% 4261
2021
Q4 		$1.32M Sell
92,183
-54,208
-37% -$823K ﹤0.01% 3877
2021
Q3 		$2.93M Buy
146,391
+95,669
+189% +$1.69M ﹤0.01% 3345
2021
Q2 		$1.12M Sell
50,722
-24,950
-33% -$688K ﹤0.01% 4136
2021
Q1 		$2.57M Buy
75,672
+75,472
+37,736% +$3.01M ﹤0.01% 3474
2020
Q4 		$8K Buy
+200
New +$9.15K ﹤0.01% 6056

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Wells Fargo's ABCL Position: Q2 2026 in Review

Wells Fargo increased its AbCellera Biologics (ABCL) stake by 279% in Q2 2026, buying an estimated $217K and bringing the position to 60,335 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #4673.

Wells Fargo first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.93M in Q3 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Wells Fargo held 60,335 shares of AbCellera Biologics worth $474K as of Q2 2026.
  • Wells Fargo bought 44,435 AbCellera Biologics shares in Q2 2026, an estimated $217K.
  • AbCellera Biologics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4673 holding.
  • Wells Fargo first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Wells Fargo's AbCellera Biologics position peaked at $2.93M in Q3 2021.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.